Gray Matter Demyelination in Primary Progressive MS at 7T

January 26, 2024 updated by: Hartwig R. Siebner, Danish Research Centre for Magnetic Resonance

Investigating Cortical Gray Matter Demyelination in Primary Progressive Multiple Sclerosis at 7 Tesla

Progressive-onset multiple sclerosis (PPMS) occurs in about 15% of all people living with MS. PPMS remains understudied, and most disease-modifying treatments are ineffective for PPMS. To date, it is unknown why some people progress immediately from MS onset. The present study will assess the role of gray matter in PPMS by characterizing it with ultra-high field magnetic resonance imaging (MRI). While both white and gray matter are affected in relapsing MS, in PPMS tissue damage is primarily in the cortex. Cortical gray matter consists largely of neuronal cell bodies, which send electrical signals to create a functional response, such as arm or leg movement. While white matter damage slows the signal response, cortical damage inhibits the initial creation of electrical signals. There is a great need to research and develop scientific biomarkers to identify and monitor progression and repair in PPMS. In this project, 7 Tesla MRI is used to investigate the cortical gray matter in people with PPMS. 7 Tesla MRI is the safest and most detailed way to study the brain. Because the cortex is only a few millimeters thick, it has been traditionally difficult to investigate. At 7 Tesla, different layers and lesions within the cortex can be seen. In addition, this project will use myelin-sensitive MRI to determine the biological underpinnings of both cortical lesions and the 'normal appearing' cortical damage in PPMS. This will answer relevant questions about the brain's capacity for repair, the extent of demyelination and the occurrence of inherent cortical remyelination and provides an avenue for the development of novel clinical MR biomarkers tailored to PPMS.

Study Overview

Status

Recruiting

Conditions

Detailed Description

PURPOSE:

PPMS presents very differently from relapsing-remitting MS. Spinal cord involvement is greater and motor impairment significantly outweighs sensory symptoms. Contrast-enhancing lesions are infrequent in PPMS. Instead, gray matter atrophy and cortical demyelination occur at greater rates than in relapsing MS. Cortical involvement is prognostically relevant. MRI at standard clinical field strengths (e.g. 1.5 and 3 Tesla) has clear limitations for visualizing cortical damage. In particular, demyelination at the outer cortical layers is underestimated. Although 7 Tesla MRI is known to be superior to clinical MRI, myelin imaging has not yet been widely explored at 7 Tesla.

STUDY AIMS:

Use anatomical and quantitative MRI at 7 Tesla to identify radiologically visible and invisible features of cortical gray matter damage that contribute to physical and cognitive impairment in PPMS.

The specific project aims are

  1. to utilize submillimeter anatomical MRI to map the distribution of the different types of cortical lesions in PPMS and assess cortical lesion volume and burden
  2. to characterize and compare cortical lesions, perilesional gray and white matter as well as normal appearing gray matter (NAGM) using quantitative MR sequences
  3. to explore the relationship between volumetric and myelin-measures with clinical scores in order to determine the best predictor of progression in PPMS

RESEARCH PLAN:

The investigators will enrol 30 primary-progressive MS subjects and 30 age- and sex-matched healthy controls to participate in two days of MRI experiments.

Whole-brain imaging will be performed on both days at Hvidovre Hospital on a research-only 7 Tesla Philips Achieva (Best, The Netherland) with a dual transmit, 32-channel receive head coil (Nova Medical).

Day 1: Submillimeter resolution anatomical images are collected for tissue segmentation, lesion identification, the assessment of central veins and paramagnetic rims.

In addition, a battery of physical and cognitive testing with a focus in sensorimotor hand function and cognitive processing speed will be performed, assessing two prominent symptoms of PPMS.

Day 2: Quantitative, spectroscopic (MRS) and functional MRI (fMRI) for the assessment of myelin.

ANALYSIS:

The main analysis will consist of cortical lesion identification, segmentation of both lesions and cortex and the assessment of the MRI myelin measures in both the lesions and NAGM. Control data will be used to establish a baseline measure of myelination. Myelin content in the different types of lesions and NAGM will be compared.

All statistical analysis will be performed in R. Linear and mixed effects modelling will determine how clinical, structural and MRI measures contribute to physical and cognitive performance, and will allow to extract the most relevant MR predictors of the clinical scores.

In part, the analysis will merge the acquired data with data from an ongoing study on structural and functional assessments for sensorimotor function in relapsing-remitting (RRMS) and secondary progressive MS (SPMS) (NCT03653585). This will allow to place the PPMS cohort directly in the context of other subtypes of MS.

The present study will significantly enhance the understanding of cortical damage in PPMS, the main contributor to chronic impairment. The non-invasive characterization of cortical lesions, structurally and in terms of myelin, will answer relevant questions about the brain's capacity for repair, the extent of demyelination and the occurrence of inherent cortical remyelination.

Study Type

Observational

Enrollment (Estimated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Denmark
      • Hvidovre, Denmark, 2650
        • Recruiting
        • Danish Research Centre for Magnetic Resonance
        • Contact:
        • Principal Investigator:
          • Vanessa Wiggermann, PhD
        • Principal Investigator:
          • Hartwig R Siebner, Prof

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

30 healthy control volunteers will be recruited from the general population via the departments webpage (www.drcmr.dk), publicly available advertising media 'http://www.forsoegsperson.dk/', links on social media portal: 'facebook' and advertisements in newsstands and communication-boards in public facilities like canteens, educational institutions, sports facilities and hospitals in the Copenhagen area.

Recruitment of 30 patients will be done through the ambulatory care at the Danish Multiple Sclerosis Center (DMSC) at Rigshospitalet in Copenhagen, Denmark.

Description

PATIENTS

Inclusion Criteria:

  • Diagnosed with primary progressive multiple sclerosis
  • Expanded Disability Status Scale of ≤ 6.5
  • No clinical relapse within last three months
  • Have the ability to comply with all requirements of the study protocol, as determined by the investigator

Exclusion Criteria:

  • Pregnancy
  • Pacemaker or other implanted electronic devices
  • Claustrophobia
  • Psychiatric disorder
  • Administration of acute cortisol
  • Changes in pharmacological treatment within the last 3 months
  • Any contraindication to MRI
  • Persons who do not wish to be informed about abnormal findings as part of the investigations

HEALTHY CONTROLS

Inclusion Criteria:

  • Able bodied
  • Have the ability to comply with all requirements of the study protocol, as determined by the investigator

Exclusion Criteria:

  • Pregnancy
  • Under medication at the time of the experiment (with the exception of contraceptive drugs)
  • History of neurologic disease
  • Pacemaker or other implanted electronic devices
  • History of cerebral hemorrhage or brain damage
  • Claustrophobia
  • Psychiatric disorder
  • Any contraindication to MRI
  • Persons who do not wish to be informed about abnormal findings as part of the investigations

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Primary Progressive MS (PPMS)
Clinically definite MS patients with identified primary-progressive disease onset, within 10 years of diagnosis
Non-neurological controls (HC)
Age and sex matched to the PPMS patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Distribution of cortical lesions in PPMS
Time Frame: Baseline
Three different types of cortical lesions will be quantified across all cortical areas (Leuko- and Intracortical, Subpial). Their number in each area will be compared to existing data of RRMS and SPMS patients. Most patients are expected to show cortical lesions. It will be assessed which areas of the cortex are affected earliest in PPMS.
Baseline
Volume of cortical lesions in PPMS
Time Frame: Baseline
The volume of the different cortical lesion subtypes [in cubic mm] will be quantified and compared to lesion volumes in RRMS and SPMS patients. It will be assessed which type of damage, i.e. which of the three lesion types, drives motor and cognitive impairment using linear regression models. The investigators hypothesize that more extensive cortical demyelination will relate to lower/worse test scores.
Baseline
Identify central veins and the presence of paramagnetic rims for cortical lesions
Time Frame: Baseline
Susceptibility-sensitive imaging data will be pre-processed as described in literature and co-registered with other anatomical MRI data. It will be assessed whether the location of veins or paramagnetic rims matches areas of already identified lesions. Although central veins have gained large attention in white matter lesions as an additional diagnostic criterium, their presence and role in cortical lesions is less well understood. Paramagnetic rims of MS lesions have been identified as highly relevant predictors of active disease progression. Their prevalence in PPMS [in %] will be assessed and relationships to clinical, behavioural and MRI metrics will be explored in mixed effects models that account for other patients specific (age, gender, disease duration, EDSS) or lesion-specific variables (volume, lesion subtype).
Baseline
Quantitative assessment of myelin density in cortical lesions, perilesional gray and white matter, and normal appearing cortex using myelin water imaging
Time Frame: Baseline
On a group level, the myelin water fraction [in %] will be compared between cortical lesion subtypes and the normal appearing cortex. Lesions and normal appearing cortex are expected to have lower myelin density than cortical gray matter in non-neurological individuals. The variance in myelin density among lesions is expected to be high as various degrees of demyelination and remyelination may be present. Remyelination capacity of cortical lesions may be higher than in white matter lesions and thus myelin differences between cortical lesions and normal appearing cortex may be small. Myelin water fraction values will be assessed relative to clinical and behavioural metrics in mixed effects models. The investigators hypothesize that lower myelin densities, in addition to the volume of cortical demyelination, will relate to lower/worse test scores.
Baseline
Quantitative assessment of magnetization transfer in cortical lesions, perilesional gray and white matter, and normal appearing cortex
Time Frame: Baseline
Similarly, magnetization transfer indices will be assessed between lesion subtypes, normal appearing cortex and compared to cortical gray matter in non-neurological individuals. Instead of assessing directly the relaxation times of different water environments, MT provides an indirect assessment of the interaction of mobile and bound protons. Here, the macromolecular bound pool signal fraction [in %] will be assessed relative to clinical and behavioural metrics in mixed effects models. The investigators hypothesize that smaller pool fractions, in addition to the volume of cortical demyelination, will relate to lower/worse test scores.
Baseline
Quantitative assessment of fractional anisotropy in cortical lesions, perilesional gray and white matter, and normal appearing cortex using diffusion tensor imaging data
Time Frame: Baseline
Fractional anisotropy (FA) is a commonly used diffusion metric for the assessment of tightly packed, myelinated axons in white matter. FA and other diffusion metrics will be compared between the cortical lesion subtypes and the normal appearing cortex. On average, lower microstructural anisotropy is expected in lesions as a reflection of demyelination and partial axonal loss. FA values will be assessed relative to clinical and behavioural metrics in mixed effects models. The investigators hypothesize that lower FA, in addition to the volume of cortical demyelination, will relate to lower/worse test scores.
Baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of cortical lesions in the primary sensorimotor cortex (SM1)
Time Frame: Baseline
Quantified as cortical lesion number on a unihemispheric level. The extent of damage to the SM1 is unknown, but based on clinical symptoms of motor function up to 40% of patients are expected to show focal cortical lesions in this area. The relationship between SM1 cortical lesion numbers and other MRI metrics (e.g. white matter lesion load of the corticospinal tract, cortical myelination, cortical thickness, metabolite levels of SM1-HAND and diffusion metrics of the corticospinal tract) will be assessed.
Baseline
Cortical lesion volume in the primary sensorimotor cortex (SM1)
Time Frame: Baseline
Cortical lesion volume is assessed on a unihemispheric level. Due to variable lesion size, the extent of damage to the SM1 may be better captured in terms of volume [cubic mm] than lesion number. The relationship between SM1 cortical lesion volume and other MRI metrics (e.g. white matter lesion load of the corticospinal tract, cortical myelination, cortical thickness, metabolite levels of SM1-HAND and diffusion metrics of the corticospinal tract) will be assessed.
Baseline
Motor function
Time Frame: Baseline
Upper and lower limb motor performance are assessed by 9-hole peg test and timed 25-foot walk. The investigators anticipate relationships of these scores with white matter integrity of motor tracts in the brain (corticospinal tract) and spinal cord cross sectional area (assessed on 3D MPRAGE data).
Baseline
Sensory acuity
Time Frame: Baseline
Sensory acuity is assessed as part of the EDSS on a scale between 1 and 5. The investigators anticipate relationships of these scores with white matter integrity of sensory tracts in the brain (corticospinal tract) and spinal cord cross sectional area (assessed on 3D MPRAGE data).
Baseline
Regional metabolite concentration of the SM1
Time Frame: Baseline
Measured as N-acetylaspartate (NAA) concentration derived from MRS of a 2x2x2 voxel of the primary sensorimotor hand area. The NAA concentration within a lesioned hemisphere is expected to be decreased and to correlate with motor function, sensory acuity and regional myelin density. In addition, glutamate will be assessed, which is expected to be lower in PPMS than in HCs, and myo-inositol, which has been reported to be increased in RRMS compared to HCs. All metabolite concentrations are measured in [mM].
Baseline
Functional MRI data for the assessment of temporal synchronization
Time Frame: Baseline
A paradigm of finger movement paced by a visual cue will be used in a fMRI experiment to measure temporal synchronization as a proxy of sensorimotor organization and cortical myelination. The investigators anticipate reduced synchronization with higher EDSS and lower myelin density.
Baseline
Cognitive performance and relationship to MRI measures (Exploratory)
Time Frame: Baseline
Cognitive performance related to information processing speed and encoding, recall and recognition is assessed using the symbol digit modalities test (SDMT) and the California Verbal Learning Test (CVLT II). In an exploratory analysis, it will be assessed if cognitive performance scores relate to myelin changes in specific areas of the brain, both in gray and white matter, and whether there is a relationship with cortical lesion load.
Baseline

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Depression
Time Frame: Baseline
Depression score from the Beck depression inventory II (BDI-II) questionnaire (range 0-63, lower being less depressed).
Baseline
Fatigue
Time Frame: Baseline
Fatigue will be assessed using the Fatigue Scale for Motor and Cognitive Functions (FSMC), 20 item questionnaire (10 motor, 10 cognitive items) with each item's response rated on a 5-point Likert scale. Lower scores indicate less fatigue.
Baseline
Morphometric measures: Whole brain cortical volume and white matter lesion volume (covariate)
Time Frame: Baseline
Volume of cortical gray matter and white matter lesion volume [cubic mm] derived from segmented MR images.
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Danish Research Centre for Magnetic Resonance

Collaborators

Scleroseforeningen
Danish Multiple Sclerosis Center

Investigators

  • Principal Investigator: Vanessa Wiggermann, PhD, Danish Research Centre for Magnetic Resonance
  • Study Director: Hartwig R Siebner, Prof, Danish Research Centre for Magnetic Resonance

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 30, 2021

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

December 1, 2024

Study Registration Dates

First Submitted

April 6, 2021

First Submitted That Met QC Criteria

July 15, 2021

First Posted (Actual)

July 27, 2021

Study Record Updates

Last Update Posted (Estimated)

January 29, 2024

Last Update Submitted That Met QC Criteria

January 26, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A40219

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

In accordance with Danish data protection legislation, it is currently not allowed to publish individual participant data.

Data that underlie published results related to the primary and secondary outcome measures will, following anonymization, be made publicly available. However, data will be grouped in appropriate age categories with minimum 5 participants in each group.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Progressive Multiple Sclerosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe